About Mogrify

Mogrify develops in vivo reprogramming therapies that utilize a proprietary platform to identify key transcriptomic and epigenetic factors necessary for direct cellular conversion. This technology aims to restore lost cell types in patients with degenerative diseases, particularly in otology, ophthalmology, and diabetes, addressing significant unmet clinical needs.

```xml <problem> Many degenerative diseases result in the loss of specific cell types, leading to organ dysfunction and unmet clinical needs in areas like otology, ophthalmology, and diabetes. Current treatment options often fail to restore the lost cells directly in vivo. </problem> <solution> Mogrify is developing a novel class of in vivo reprogramming therapies to regenerate functional cells lost due to degenerative diseases. The company's proprietary MOGRIFY® and epiMOGRIFY® platforms use a systematic, big-data driven approach to identify optimal combinations of transcription factors and growth factors needed for direct cellular reprogramming and maintenance of cell identity. These platforms leverage next-generation sequencing, gene regulatory, and epigenetic network data to predict factors required to produce any target cell type from any source cell type. This approach enables the company to enhance existing stem-cell forward programming methods or bypass development pathways altogether, affecting direct transdifferentiation between mature cell types. </solution> <features> - MOGRIFY® platform for direct cellular reprogramming using transcriptomic data - epiMOGRIFY® platform for maintaining cell identity using epigenetic data - Identification of optimal transcription factor combinations for cell conversion - Prediction of growth factors required for target cell type production - Ability to enhance stem-cell forward programming or bypass developmental pathways - Focus on in vivo reprogramming for regenerative medicine applications - Applicability across otology, ophthalmology, diabetes, and other degenerative diseases </features> <target_audience> The primary target audience includes patients suffering from degenerative diseases such as sensorineural hearing loss, vision loss, and diabetes, as well as pharmaceutical companies seeking co-development partnerships in regenerative medicine. </target_audience> <revenue_model> Mogrify generates revenue through in vivo reprogramming therapy development, co-development partnerships with pharmaceutical companies, and exploitation of its platform in other therapeutic and non-therapeutic applications. </revenue_model> ```

What does Mogrify do?

Where is Mogrify located?

Mogrify is based in Cambridge, United Kingdom.

When was Mogrify founded?

Mogrify was founded in 2019.

How much funding has Mogrify raised?

Mogrify has raised 49880000.

Location

Cambridge, United Kingdom

Founded

2019

Funding

49880000

Employees

39 employees

Find Investable Startups and Competitors

Search thousands of startups using natural language

AI voice (2021+)underground pipe robots energy flexibility software

Start Searching

Mogrify

⚠️ AI-generated overview based on web search data – may contain errors, please verify information yourself! You can claim this account with your email domain to make edits.

Executive Summary

mogrify.co.uk 7K+

Founded 2019 – Cambridge, United Kingdom

Funding

Estimated Funding

$20M+

Team (30+)

No team information available.

Company Description

Problem

Many degenerative diseases result in the loss of specific cell types, leading to organ dysfunction and unmet clinical needs in areas like otology, ophthalmology, and diabetes. Current treatment options often fail to restore the lost cells directly in vivo.

Solution

Mogrify is developing a novel class of in vivo reprogramming therapies to regenerate functional cells lost due to degenerative diseases. The company's proprietary MOGRIFY® and epiMOGRIFY® platforms use a systematic, big-data driven approach to identify optimal combinations of transcription factors and growth factors needed for direct cellular reprogramming and maintenance of cell identity. These platforms leverage next-generation sequencing, gene regulatory, and epigenetic network data to predict factors required to produce any target cell type from any source cell type. This approach enables the company to enhance existing stem-cell forward programming methods or bypass development pathways altogether, affecting direct transdifferentiation between mature cell types.

Features

MOGRIFY® platform for direct cellular reprogramming using transcriptomic data

epiMOGRIFY® platform for maintaining cell identity using epigenetic data

Identification of optimal transcription factor combinations for cell conversion

Prediction of growth factors required for target cell type production

Ability to enhance stem-cell forward programming or bypass developmental pathways

Focus on in vivo reprogramming for regenerative medicine applications

Applicability across otology, ophthalmology, diabetes, and other degenerative diseases

Target Audience

The primary target audience includes patients suffering from degenerative diseases such as sensorineural hearing loss, vision loss, and diabetes, as well as pharmaceutical companies seeking co-development partnerships in regenerative medicine.

Revenue Model

Mogrify generates revenue through in vivo reprogramming therapy development, co-development partnerships with pharmaceutical companies, and exploitation of its platform in other therapeutic and non-therapeutic applications.